Loading...
XSTO
EXPRS2
Market cap5mUSD
, Last price  
SEK
Name

ExpreS2ion Biotech Holding AB

Chart & Performance

D1W1MN
XSTO:EXPRS2 chart
No data to show
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-30.66%
Rev. gr., 5y
-26.27%
Revenues
3m
-57.26%
6,664,9616,615,05604,652,0009,795,0008,868,00013,829,0005,259,00012,234,0005,086,0007,050,0003,013,000
Net income
-36m
L-60.16%
688,660279,308-8,438,149-8,538,000-9,835,000-16,822,000-16,703,000-31,713,000-43,925,000-118,605,000-91,401,000-36,415,000
CFO
-34m
L-66.37%
-7,021,000-8,608,000-12,879,000-12,691,000-18,175,000-45,646,000-99,614,000-100,887,000-33,928,000
Earnings
May 30, 2025

Profile

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.
URL
https://www.expres2ionbio.com
IPO date
Jul 29, 2016
Employees
32
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,013
-57.26%
7,050
38.62%
5,086
-58.43%
Cost of revenue
32,337
55,066
76,405
Unusual Expense (Income)
NOPBT
(29,324)
(48,016)
(71,319)
NOPBT Margin
Operating Taxes
(8,148)
(8,566)
(7,976)
Tax Rate
NOPAT
(21,176)
(39,450)
(63,343)
Net income
(36,415)
-60.16%
(91,401)
-22.94%
(118,605)
170.02%
Dividends
Dividend yield
Proceeds from repurchase of equity
42,340
60,719
75,960
BB yield
-79.16%
-62.36%
-12.18%
Debt
Debt current
360
275
1,763
Long-term debt
2,872
176
Deferred revenue
Other long-term liabilities
1,437
1,914
Net debt
(81,181)
(54,475)
(110,592)
Cash flow
Cash from operating activities
(33,928)
(100,887)
(99,614)
CAPEX
(870)
(2,015)
(383)
Cash from investing activities
21,275
(2,015)
105,325
Cash from financing activities
34,871
47,836
61,460
FCF
(20,942)
(40,309)
(61,003)
Balance
Cash
81,541
57,597
110,974
Long term investments
25
1,557
Excess cash
81,390
57,270
112,277
Stockholders' equity
11,815
(934,488)
(235,324)
Invested Capital
54,402
1,001,563
342,416
ROIC
ROCE
EV
Common stock shares outstanding
2,596
46,149
37,739
Price
20.60
876.30%
2.11
-87.24%
16.53
-55.03%
Market cap
53,488
-45.07%
97,373
-84.39%
623,821
-47.38%
EV
(27,693)
42,898
752,732
EBITDA
(29,324)
(46,417)
(70,103)
EV/EBITDA
0.94
Interest
727
501
871
Interest/NOPBT